The device is the first BA9™-eluting dedicated bifurcation stent, complementing the existing BioMatrix family of product. It features our PLA/BA9™ technology, with an abluminal* biodegradable coating.
* The coating is applied primarily on the abluminal surface.

The first head-to-head randomized study between the two Drug-Eluting Stent systems (DES) in a ‘real world, all comers’ population using clinical results as a primary endpoints.

Significant lower risk in the patient-related composite endpoint of death, MI, and any repeat revascularization at 3 years (Windecker, S., oral presentation, EuroPCR 2011)

Wednesday, 08 February 2012
  6 AM EST
12 PM CET
  7 PM Singapore/HK time
Biosensors will announce its results for the third quarter of its financial year 2012 ended 31 December 2011, on 08 February 2012 after trading hours on the Singapore Stock Exchange.